Issue #3 – ALWAYS FRESH

We’re thrilled to welcome any CIDPedia subscriber to our expanded family—you’re not losing your trusted CIDP resource, you’re gaining so much more. As we merge with CIDPedia, we remain unwavering in our mission: to provide accurate information, heartfelt stories, and practical guidance for patients, caregivers, and professionals. This evolution harnesses cutting-edge AI insights alongside our lived experience with CIDP, as well as deep research capabilities. We use our visions to bring you richer content—research guides, expert interviews, community spotlights, and creative features—without sacrificing the trusted clarity you’ve come to expect. Thank you for your loyalty and patience as we grow together. Here’s to even greater connection, support, and “trusted CIDP insight” in every issue ahead.

Multidisciplinary Clinics Revolutionize Care
UT Health San Antonio and Baylor Dallas now integrate neurologists, geneticists, and rehabilitation specialists under one roof—slashing diagnosis time from 18 months to 6 weeks for complex cases.

Long-Acting Immunotherapy Approved
FDA approves 12-week dosing intervals for refractory neuro-inflammatory conditions, cutting infusion burden by 50% while maintaining therapeutic efficacy.

Statewide Telehealth Expansion
All major Texas insurers extend virtual neurology consultation coverage through 2027, eliminating geographic barriers for rural patients.

Predictive Wearables Go Live
Three FDA-cleared smartphone apps predict disease flares 5-7 days early through gait and tremor analysis—Medicare coverage decision pending Q4.

Revolutionary CIDP Breakthrough: 2025 Treatment Transformation

Efgartigimod (Vyvgart Hytrulo) Dominates Clinical Practice
The first plasma-free CIDP therapy delivers weekly subcutaneous injections, reducing pathogenic antibodies by 66.4% within 29 days. Texas state parity laws mandate coverage—Aetna, BCBS, and United now covering all qualified patients with streamlined prior authorization.neurologylive+1

Riliprubart: Complement Pathway Innovation
Sanofi's first-in-class C1s complement inhibitor achieves 88% patient improvement in Phase 2 trials. Two Phase 3 studies (MOBILIZE and VITALIZE) actively recruiting across Texas medical centers, targeting treatment-refractory patients.sanofi+1

Home Infusion Infrastructure Explosion
Texas certified SCIG providers surge from 12 to 47 locations. HealthQuest Houston, Soleo Health, and UT Health East Texas lead comprehensive programs with 24/7 nursing support and same-day emergency scheduling.soleohealth+1

Clinical Trial Gold Rush
12 active CIDP trials enrolling statewide:

Insurance Victory
Texas eliminates step-therapy requirements for FDA-approved CIDP treatments. Manufacturer patient assistance programs now cover up to $15,000 annually in out-of-pocket costs .ispor

Texas Rare Disease Registry
Statewide patient database linking directly to clinical trials and specialist referrals across Houston, Dallas, San Antonio, and Austin medical centers.
Register at NORD Texas Programs

Financial Aid Navigator
Comprehensive grant opportunities covering travel, equipment, and treatment costs—with dedicated Texas rare disease funding streams now available.
Apply for NORD RareCare Assistance

Peer Mentor Network
One-on-one matching with experienced CIDP patients for treatment guidance, insurance navigation, and emotional support via phone or secure messaging.
Request peer match at Texas Parent to Parent

Clinical Trial Fast-Track
Live database of Texas-based rare neuro studies with accelerated enrollment protocols reducing wait times from months to weeks.
Search trials at UT Southwestern

Gene Therapy Milestone Achievement
Baylor College's AAV9 trial for hereditary neuropathies reports 80% motor improvement at 6 months—pediatric enrollment opens Q4 2025.

$50M Precision Medicine Initiative
University of Texas System secures federal funding for unified rare-disease genomic database spanning all four medical hubs, accelerating personalized treatment pathways.

Policy Victory: Coverage Parity Mandate
Texas Department of Insurance requires insurers to cover FDA-approved rare disease therapies at standard treatment levels—eliminating discriminatory step-therapy hurdles.

Meet Sarah, a 34-year-old Austin teacher diagnosed with CIDP in 2023. Initially battling crushing fatigue and muscle weakness, Sarah discovered hope through community support and efgartigimod treatment.

"The peer connections and access to breakthrough therapies completely changed my trajectory," Sarah shares. "I'm teaching full-time again and completed my first 5K last month. For anyone struggling—there's always hope with CIDP."

Q: What's the frequency for new long-acting immunotherapy?
A: Newly approved treatments allow 12-week dosing intervals—reducing infusion frequency by 50% compared to traditional IVIg protocols.

Q: Are there CIDP-specific dietary recommendations?
A: While no specific CIDP diet exists, patients report benefits from anti-inflammatory protocols rich in omega-3 fatty acids, fruits, and vegetables. Consult your neurologist for personalized guidance.

Q: How do I find local CIDP support groups?
A: Access gbs-cidp.org/support-groups for Texas-wide virtual and in-person groups, plus our peer mentor matching program.

CIDP: Chronic Inflammatory Demyelinating Polyneuropathy
IVIg: Intravenous Immunoglobulin
SCIG: Subcutaneous Immunoglobulin
AAV9: Adeno-Associated Virus serotype 9
PA: Prior Authorization

TNR Issue #3 showcases Texas's leadership in rare neuro care—from revolutionary CIDP treatments to statewide support networks. By addressing access barriers, insurance complexities, and resource fragmentation, we empower every Texan to move from struggle to strength. Share this issue with anyone navigating rare neurological conditions.

Stay informed. Stay connected. Always STAY FRESH.

Verified Resource Links:

Neighborly Texas Note & Human Disclaimer:
We’re a small Texas-based team sharing hard-won knowledge, deep research, and lived experience from the front lines of rare and chronic illness. Our goal is to serve our Texas neighbors and the broader rare disease community with honesty, kindness, and clarity. We are not doctors, and nothing here is medical advice—always consult your healthcare provider for personal decisions. What works for one person may not work for another. While we source the best information available, rare disease science and AI are always evolving. We respect your privacy, honor your Texas-sized courage, anonymize all stories (unless you say otherwise), and never let sponsors influence our content. If something feels off or unclear, let us know—your feedback keeps us grounded and true to our mission. When in doubt, talk with your doctor—then come pull up a chair and share your story.

Sponsor Note: Partner With Texas Neurorare
Committed sponsors and mission-aligned partners help us keep information open and support flowing across Texas and beyond—always without compromising our editorial integrity. Interested in joining the cause? Reach out to us to learn how together, we can uplift the rare disease community.

Richard & Margaret | www.cidpedia.net
Fight fierce, fight hard, fight smart.